Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each

Bulletin Express07-08 18:45

Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration to HKD 9,420.

The repurchased shares—equivalent to 0.00027 % of the company’s 223.37 million issued shares (excluding treasury shares) prior to the transaction—have been retained as treasury shares, lifting the treasury-share balance to 3.70 million. After the buyback, the company’s total issued share count remains unchanged at 227.07 million.

The repurchase forms part of a mandate approved on 29 May 2026 that authorises Qyuns Therapeutics to buy back up to 22.44 million shares. Cumulative repurchases under this mandate now stand at 990,200 shares, representing 0.4413 % of the outstanding share capital at the date the mandate was granted.

In line with Hong Kong listing regulations, Qyuns Therapeutics is subject to a moratorium on issuing new shares or transferring treasury shares until 7 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133345069?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133345069","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration to HKD 9,420.</p>\n<p>The repurchased shares—equivalent to 0.00027 % of the company’s 223.37 million issued shares (excluding treasury shares) prior to the transaction—have been retained as treasury shares, lifting the treasury-share balance to 3.70 million. After the buyback, the company’s total issued share count remains unchanged at 227.07 million.</p>\n<p>The repurchase forms part of a mandate approved on 29 May 2026 that authorises Qyuns Therapeutics to buy back up to 22.44 million shares. Cumulative repurchases under this mandate now stand at 990,200 shares, representing 0.4413 % of the outstanding share capital at the date the mandate was granted.</p>\n<p>In line with Hong Kong listing regulations, Qyuns Therapeutics is subject to a moratorium on issuing new shares or transferring treasury shares until 7 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-08 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration to HKD 9,420.</p>\n<p>The repurchased shares—equivalent to 0.00027 % of the company’s 223.37 million issued shares (excluding treasury shares) prior to the transaction—have been retained as treasury shares, lifting the treasury-share balance to 3.70 million. After the buyback, the company’s total issued share count remains unchanged at 227.07 million.</p>\n<p>The repurchase forms part of a mandate approved on 29 May 2026 that authorises Qyuns Therapeutics to buy back up to 22.44 million shares. Cumulative repurchases under this mandate now stand at 990,200 shares, representing 0.4413 % of the outstanding share capital at the date the mandate was granted.</p>\n<p>In line with Hong Kong listing regulations, Qyuns Therapeutics is subject to a moratorium on issuing new shares or transferring treasury shares until 7 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1133345069","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133345069","pubTimestamp":1783507514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics执行少量股票回购；以每股15.70港元的价格向库中增加600股H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. announced that on 8 July 2026 it repurchased 600 H-shares on the Hong Kong Stock Exchange at a fixed price of HKD 15.70 per share, bringing the total cash consideration to HKD 9,420.\nThe repurchased shares—equivalent to 0.00027 % of the company’s 223.37 million issued shares (excluding treasury shares) prior to the transaction—have been retained as treasury shares, lifting the treasury-share balance to 3.70 million. After the buyback, the company’s total issued share count remains unchanged at 227.07 million.\nThe repurchase forms part of a mandate approved on 29 May 2026 that authorises Qyuns Therapeutics to buy back up to 22.44 million shares. Cumulative repurchases under this mandate now stand at 990,200 shares, representing 0.4413 % of the outstanding share capital at the date the mandate was granted.\nIn line with Hong Kong listing regulations, Qyuns Therapeutics is subject to a moratorium on issuing new shares or transferring treasury shares until 7 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133345069","isCrawlerRequest":true}